SRDX - Surmodics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
42.44
+2.92 (+7.39%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close39.52
Open39.65
Bid42.45 x 800
Ask42.88 x 1000
Day's Range39.65 - 43.10
52 Week Range38.06 - 82.35
Volume155,370
Avg. Volume123,825
Market Cap568.594M
Beta (3Y Monthly)1.79
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateNov 14, 2017 - Nov 20, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est70.00
  • Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics
    Zacks9 days ago

    Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics

    Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics

  • 5 Stocks to Keep an Eye on as Analysts Initiate Coverage
    Zacks10 days ago

    5 Stocks to Keep an Eye on as Analysts Initiate Coverage

    More analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

  • Did Surmodics, Inc. (NASDAQ:SRDX) Insiders Sell Shares?
    Simply Wall St.15 days ago

    Did Surmodics, Inc. (NASDAQ:SRDX) Insiders Sell Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Hedge Funds Have Never Been This Bullish On SurModics, Inc. (SRDX)
    Insider Monkey17 days ago

    Hedge Funds Have Never Been This Bullish On SurModics, Inc. (SRDX)

    Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
    Zacks19 days ago

    Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates

    Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.

  • Thomson Reuters StreetEvents22 days ago

    Edited Transcript of SRDX earnings conference call or presentation 1-May-19 9:00pm GMT

    Q2 2019 Surmodics Inc Earnings Call

  • SurModics (SRDX) Q2 2019 Earnings Call Transcript
    Motley Fool23 days ago

    SurModics (SRDX) Q2 2019 Earnings Call Transcript

    SRDX earnings call for the period ending March 31, 2019.

  • Associated Press24 days ago

    SurModics: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Eden Prairie, Minnesota-based company said it had net income of 9 cents. Earnings, adjusted for non-recurring gains, were 7 cents per share. The drug delivery technology company ...

  • Business Wire24 days ago

    Surmodics Reports Second Quarter Fiscal 2019 Results

    Updates Fiscal 2019 Guidance

  • Earnings Preview: SurModics (SRDX) Q2 Earnings Expected to Decline
    Zackslast month

    Earnings Preview: SurModics (SRDX) Q2 Earnings Expected to Decline

    SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wirelast month

    Surmodics to Webcast Second Quarter Fiscal 2019 Earnings Conference Call on May 1

    Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2019 conference call on Wednesday, May 1, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon. Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will recap the second quarter fiscal 2019 financial results and accomplishments.

  • Business Wirelast month

    Surmodics Sublime™ Guide Sheath Receives FDA 510(k) Approval

    Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Sublime™ guide sheath. “Surmodics continues to make progress in the development of clinically important and innovative technologies,” said Gary Maharaj, Surmodics President and CEO. Radial artery access has been widely adopted for use in coronary procedures where devices have been developed to accommodate that need.

  • Business Wirelast month

    Surmodics Provides Update Regarding TRANSCEND Clinical Trial

    Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, has resumed patient enrollment into its TRANSCEND clinical trial and is nearly 75 percent of the way to its goal of 446 randomized patients. Patient enrollment in TRANSCEND, the pivotal clinical trial for the SurVeil™ drug-coated balloon (DCB), was temporarily paused following the March 15 publication of a Food & Drug Administration (FDA) letter to physicians.

  • Shareholders Are Thrilled That The Surmodics (NASDAQ:SRDX) Share Price Increased 132%
    Simply Wall St.last month

    Shareholders Are Thrilled That The Surmodics (NASDAQ:SRDX) Share Price Increased 132%

    It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But when you pick a company that is really flourishing, you can make more than 100%. For exam...

  • Business Wire2 months ago

    Surmodics to Present at Needham Healthcare Conference

    Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will make a presentation to the investment community at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, at 1:30 p.m. ET (12:30 p.m. CT). A live audio webcast of the presentation will be available by going to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com, clicking on the webcast link and, on the conference's registration page, completing the required fields to register.

  • Why An FDA Probe Is Rocking The Boat For These Medical Device Makers
    Investor's Business Daily2 months ago

    Why An FDA Probe Is Rocking The Boat For These Medical Device Makers

    A Food and Drug Administration probe into chemotherapy drug paclitaxel is testing the waters for medical device companies SurModics, Boston Scientific, Medtronic and Becton Dickinson.

  • MarketWatch2 months ago

    Surmodics evaluating how FDA warning on paclitaxel-coated devices will affect trials of its own drug-coated balloon

    Surmodics Inc said in a securities filing Monday that it was working with the Food and Drug Administration to clarify how the agency's Friday warning about paclitaxel-coated balloons and paclitaxel-eluting stents would affect the company's clinical trial evaluating SurVeil, its drug-coated balloon for the treatment of peripheral artery disease. In the Monday filing, Surmodics said it was "currently assessing the impact of the FDA communication on the TRANSCEND clinical trial, its expectations regarding the timing of completion of patient enrollment in the TRANSCEND clinical trial and related regulatory approvals for the SurVeil DCB, and any corresponding effect on its fiscal 2019 financial guidance." The FDA first said in January that it would be evaluating the potential for increased long-term mortality after using paclitaxel-coated balloons and stents. On Friday, the agency said a preliminary analysis of three trials had "identified a potentially concerning signal of increased long-term mortality in study subjects treated with paclitaxel-coated products compared to patients treated with uncoated devices." The FDA's data followed a meta-analysis published in December in the Journal of the American Heart Association showing a possible increase in mortality after two years in patients treated with paclitaxel balloons or stents. Shares of Surmodics have gained 14% in the past three months, while the S&P 500 has gained 10.8%.

  • Here's Why You Should Buy Masimo (MASI) Stock Right Now
    Zacks2 months ago

    Here's Why You Should Buy Masimo (MASI) Stock Right Now

    Masimo (MASI) announces CE marking of its Next Generation SedLine brain function monitoring for pediatric patients.

  • BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost
    Zacks2 months ago

    BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost

    Becton, Dickinson (BDX) receives a number of regulatory approvals of late.

  • Here's Why You Should Invest in Stryker (SYK) Stock Right Now
    Zacks2 months ago

    Here's Why You Should Invest in Stryker (SYK) Stock Right Now

    Stryker (SYK) makes a few lucrative acquisitions in recent times.

  • Here's Why You Should Hold Becton, Dickinson Stock for Now
    Zacks3 months ago

    Here's Why You Should Hold Becton, Dickinson Stock for Now

    Becton, Dickinson's (BDX) MAX enteric viral panel receives FDA clearance.

  • DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors
    Zacks3 months ago

    DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors

    DENTSPLY (XRAY) expects to see solid performance in Europe and the rest of the world.

  • Here's Why You Should Buy Varian Medical (VAR) Stock Now
    Zacks3 months ago

    Here's Why You Should Buy Varian Medical (VAR) Stock Now

    Buoyed by a strong first quarter, Varian Medical (VAR) has kept its fiscal 2019 guidance intact.

  • Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates
    Zacks3 months ago

    Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates

    Merit Medical (MMSI) registers solid expansion in adjusted gross margins in fourth-quarter 2018.

  • Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues
    Zacks3 months ago

    Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues

    Veeva Systems (VEEV) continues benefiting from its flagship Vault platform in fourth-quarter fiscal 2019.